OBJECTIVE: We investigated the effects of continuous cancer gene therapy, including APC engineering and local stimulation of the immune system in a mice melanoma model. MATERIALS AND METHODS: B16 melanoma cells were injected into C57/Bl6 mice intradermally. The overlying dermis or the tumor were shot with different plasmids using a gene gun every 4th day starting 8 days after tumor implantation. Control groups were mice without any therapy or gene therapy as described above with the empty plasmid. Therapy was: group I, IL-12 and IL-2; group II, IFN-gamma/B7.1; group III, IFN-gamma/B7.1, IL-12, and IL-2. RESULTS: The median survival time of all therapy groups was significantly enhanced. The longest median survival was in the IL-12/IL-2 group. Tumor growth was reduced in all therapy groups. Control groups suffered a higher rate of metastasis and had fewer inflammatory cells at the tumor site. CONCLUSIONS: Continuous therapy with the gene gun is easy to handle and shows good results. Therapy with genes for IL-12 and IL-2 was superior to that with additional IFN-gamma/B7.1 or IFN-gamma/B7.1 alone. APC engineering is clearly less sufficient in the case of the B16 melanoma.
OBJECTIVE: We investigated the effects of continuous cancer gene therapy, including APC engineering and local stimulation of the immune system in a micemelanoma model. MATERIALS AND METHODS: B16 melanoma cells were injected into C57/Bl6 mice intradermally. The overlying dermis or the tumor were shot with different plasmids using a gene gun every 4th day starting 8 days after tumor implantation. Control groups were mice without any therapy or gene therapy as described above with the empty plasmid. Therapy was: group I, IL-12 and IL-2; group II, IFN-gamma/B7.1; group III, IFN-gamma/B7.1, IL-12, and IL-2. RESULTS: The median survival time of all therapy groups was significantly enhanced. The longest median survival was in the IL-12/IL-2 group. Tumor growth was reduced in all therapy groups. Control groups suffered a higher rate of metastasis and had fewer inflammatory cells at the tumor site. CONCLUSIONS: Continuous therapy with the gene gun is easy to handle and shows good results. Therapy with genes for IL-12 and IL-2 was superior to that with additional IFN-gamma/B7.1 or IFN-gamma/B7.1 alone. APC engineering is clearly less sufficient in the case of the B16 melanoma.
Authors: Arne Dietrich; Christoph Stockmar; Gabriela Aust; Susan Endesfelder; Anke Guetz; Ulrich Sack; Manfred Schoenfelder; Johann Hauss Journal: J Cancer Res Clin Oncol Date: 2006-01-04 Impact factor: 4.553
Authors: Armando Pérez-Torres; Jesús Vera-Aguilera; Juan Carlos Hernaiz-Leonardo; Eduardo Moreno-Aguilera; Diego Monteverde-Suarez; Carlos Vera-Aguilera; Daniel Estrada-Bárcenas Journal: Cancer Biother Radiopharm Date: 2013-07-10 Impact factor: 3.099
Authors: Cezary Skobowiat; Allen S W Oak; Tae-Kang Kim; Chuan He Yang; Lawrence M Pfeffer; Robert C Tuckey; Andrzej T Slominski Journal: Oncotarget Date: 2017-02-07